Adjuvant Chemotherapy for Small Bowel Adenocarcinoma after Curative Surgery

Dong‐Hoe Koo(Sungkyunkwan University), Tae Won Kim(Asan Medical Center), Jae‐Lyun Lee(Ulsan College), Song Cheol Kim(Ulsan College), Min‐Hee Ryu(Ulsan College), Young Joo Lee(Anne Arundel Medical Center), Sung-Cheol Yun(Ulsan College), Duck‐Jong Han(Asan Medical Center), Yoon‐Koo Kang(Ulsan College), Heung-Moon Chang(Ulsan College), Yong Sang Hong(Ulsan College)

Oncology

January 1, 2011

10.1159/000328506

Cited by 22

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

|New England Journal of Medicine|2017|3.4k

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

|New England Journal of Medicine|2019|1.5k

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

|NEJM Evidence|2022|1.4k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k